{"url_path":"/sec/sgmo/8-k/2026-07-01/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001193125-26-292501-index.html","accession_number":"0001193125-26-292501","cik":"0001001233","ticker":"SGMO","issuer_name":"SANGAMO THERAPEUTICS, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001193125-26-292501-index.html","primary_entity_key":"0001001233","primary_entity_name":"SANGAMO THERAPEUTICS, INC"},"word_count":88,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\n\nNumber\n\n  \n\nDescription\n\n16.1\n  \n[Letter from Ernst & Young LLP, dated June 30, 2026.](d113173dex161.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nSANGAMO THERAPEUTICS, INC.\n\nDated: July 1, 2026\n \n\n \nBy:\n \n\n/s/ SCOTT B. WILLOUGHBY\n\n \n\n \nName:\n \nScott B. Willoughby\n\n \n\n \nTitle:\n \nChief Legal Officer and Corporate Secretary"}